APA (7th ed.) Citation

PE, L., LH, C., A, K., JS, S., D, W., M, W., & MA, B. (2014). Pegloticase immunogenicity: The relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis research & therapy, 16(2), R60. https://doi.org/10.1186/ar4497

Chicago Style (17th ed.) Citation

PE, Lipsky, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, and Becker MA. "Pegloticase Immunogenicity: The Relationship Between Efficacy and Antibody Development in Patients Treated for Refractory Chronic Gout." Arthritis Research & Therapy 16, no. 2 (2014): R60. https://doi.org/10.1186/ar4497.

MLA (9th ed.) Citation

PE, Lipsky, et al. "Pegloticase Immunogenicity: The Relationship Between Efficacy and Antibody Development in Patients Treated for Refractory Chronic Gout." Arthritis Research & Therapy, vol. 16, no. 2, 2014, p. R60, https://doi.org/10.1186/ar4497.